Information Provided By: 
Fly News Breaks for April 18, 2018
QURE, RGNX, VYGR, ONCE, NVS, AVXS
Apr 18, 2018 | 08:25 EDT
Following AveXis (AVXS) acquisition by Novartis (NVS), Bernstein analyst Vincent Chen says the potential next target should have a strong portfolio fit and innovation-oriented scientifically-minded management teams likely comfortable with the technology platform. For acquisition targets, the analyst sees two flavors, namely late stage more de-risked gene therapy companies, for which Spark (ONCE) comes to mind, and less costly but riskier earlier-stage platforms, for which uniQure (QURE), Voyager (VYGR) and REGENXBIO (RGNX) come to mind.
News For AVXS;NVS;ONCE;VYGR;RGNX;QURE From the Last 2 Days
NVS
Apr 24, 2024 | 12:31 EDT
NVS
Apr 24, 2024 | 11:53 EDT
NVS
Apr 24, 2024 | 07:26 EDT
TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.
NVS
Apr 24, 2024 | 06:24 EDT
NVS
Apr 23, 2024 | 13:58 EDT
NVS
Apr 23, 2024 | 06:36 EDT
